Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment-experienced individual

J Clin Pharm Ther. 2016 Dec;41(6):727-729. doi: 10.1111/jcpt.12455. Epub 2016 Sep 27.

Abstract

What is known and objective: Significant progression in the treatment of chronic hepatitis C virus has been made with the introduction of direct-acting antivirals (DAAs). However, limited data are available for the retreatment of individuals who have failed multiple prior DAAs.

Case description: We report a single case of an individual who was unsuccessfully treated with five prior hepatitis C virus treatment regimens including simeprevir plus sofosbuvir who was successfully cured after treatment with ledipasvir/sofosbuvir.

What is new and conclusion: Ledipasvir/sofosbuvir may be an option for treating patients who have failed multiple prior DAA regimens; however, further research is warranted.

Keywords: Harvoni; hepatitis C virus; ledipasvir/sofosbuvir.

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Benzimidazoles / therapeutic use*
  • Female
  • Fluorenes / therapeutic use*
  • Hepacivirus / drug effects*
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Middle Aged
  • Sofosbuvir / therapeutic use*
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Benzimidazoles
  • Fluorenes
  • ledipasvir
  • Sofosbuvir